Tedizolid phosphate
Sivextro (tedizolid phosphate) is a small molecule pharmaceutical. Tedizolid phosphate was first approved as Sivextro on 2014-06-20. It is used to treat bacterial infections, bacterial skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sivextro | New Drug Application | 2023-03-10 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TEDIZOLID PHOSPHATE, SIVEXTRO, CUBIST PHARMS LLC | |||
| 2024-06-20 | GAIN | ||
| 2019-06-20 | NCE | ||
HCPCS
Code | Description |
|---|---|
| J3090 | Injection, tedizolid phosphate, 1 mg |
Clinical
Clinical Trials
40 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 3 | 2 | 6 | 1 | 4 | 16 |
| Communicable diseases | D003141 | — | — | 1 | 2 | 5 | 1 | 3 | 12 |
| Fibrosis | D005355 | — | — | — | — | — | 1 | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 1 | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Bacterial endocarditis | D004697 | EFO_1000830 | — | — | — | — | 1 | — | 1 |
| Endocarditis | D004696 | HP_0100584 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial infections | D001424 | — | A49 | 4 | — | 3 | — | 1 | 8 |
| Bacterial skin diseases | D017192 | — | — | 1 | 1 | 3 | — | 1 | 6 |
| Skin diseases | D012871 | — | L00-L99 | 1 | 1 | 2 | — | 1 | 5 |
| Infectious skin diseases | D012874 | — | — | — | 1 | 2 | — | 1 | 4 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | 1 | — | — | 1 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | — | 1 | — | — | 1 |
| Soft tissue infections | D018461 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infectious arthritis | D001170 | EFO_1001351 | M00 | — | 1 | — | — | 1 | 2 |
| Abscess | D000038 | EFO_0003030 | — | — | 1 | — | — | — | 1 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | — | — | — | 1 |
| Erysipelas | D004886 | — | A46 | — | 1 | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | — | — | — | 1 |
| Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 12 | — | — | — | — | 12 |
| Gram-positive bacterial infections | D016908 | — | — | 2 | — | — | — | — | 2 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | — | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | — | 1 |
| Wound infection | D014946 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | — | — | — | — | 1 | 1 |
| Prosthesis-related infections | D016459 | EFO_1001406 | — | — | — | — | — | 1 | 1 |
| Diabetic foot | D017719 | EFO_1001459 | — | — | — | — | — | 1 | 1 |
| Foot ulcer | D016523 | — | — | — | — | — | — | 1 | 1 |
| Osteitis | D010000 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tedizolid phosphate |
| INN | tedizolid |
| Description | Tedizolid is a member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis. It has a role as an antimicrobial agent, a drug metabolite and a protein synthesis inhibitor. It is a member of pyridines, a member of tetrazoles, an organofluorine compound, an oxazolidinone, a primary alcohol and a carbamate ester. |
| Classification | Small molecule |
| Drug class | oxazolidinone antibacterials |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](COP(=O)(O)O)OC4=O)cc3F)cn2)n1 |
Identifiers
| PDB | — |
| CAS-ID | 856867-55-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2105669 |
| ChEBI ID | 83326 |
| PubChem CID | 11234049 |
| DrugBank | DB09042 |
| UNII ID | 97HLQ82NGL (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,626 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
633 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use